Burgos, Leire
Puig, Noemi
Cedena, Maria-Teresa
Mateos, María-Victoria
Lahuerta, Juan José
Paiva, Bruno
San-Miguel, Jesús F. http://orcid.org/0000-0002-9183-4857
Article History
Received: 7 April 2020
Accepted: 4 June 2020
First Online: 22 June 2020
Ethics approval and consent to participate
: Not applicable
: Not applicable
: M.-V.M. has received honoraria from lectures or participation in advisory boards from Janssen, Celgene, Amgen, Takeda, Abbvie, Adaptive, GSK, Pharmamar, EDO, Oncopeptides. J.-J.L. reports honoraria from and membership on board of directors or advisory committees with Takeda, Amgen, Celgene, and Janssen. B.P. reports honoraria for lectures from and membership on advisory boards with Amgen, Bristol-Myers Squibb, Celgene, Janssen, Merck, Novartis, Roche, and Sanofi; unrestricted grants from Celgene, EngMab, Sanofi, and Takeda; and consultancy for Celgene, Janssen, Sanofi and Takeda. J.F.S.M. reports consultancy for Bristol-Myers Squibb, Celgene, Novartis, Takeda, Amgen, MSD, Janssen, and Sanofi and membership on board of directors or advisory committees with Takeda. The remaining authors declare no competing financial interests.